T. cruzi Diagnostic Array Reducing Cross-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for Trypanosoma cruzi infections, such as Chagas disease, face challenges with high rates of false positives and false negatives due to variability in procedures and cross-reactivity with other parasites, necessitating a more sensitive and specific method for screening and diagnosis.
Innovation Solution
A method involving substrates with individually addressable antigenic T. cruzi polypeptides is used to identify specific binding to antibodies in infected individuals, distinguishing between positive and unexposed samples, and a multicomponent panel or kit is developed for diagnosis and vaccine applications, including immobilization of these polypeptides on surfaces or nanoparticles for enhanced detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional serological tests using whole to semi-purified parasite lysates are used, then the tests can detect T. cruzi infection, but they produce high rates of false positives due to cross-reactivity with antibodies developed against other parasites
Solution Approach 1:
The patent divides the complex parasite lysate into individual discrete antigens arranged in an array format. Each antigen is separately presented to the sample, allowing specific binding patterns to be identified. This segmentation enables differentiation between specific T. cruzi antibodies and non-specific cross-reactive antibodies, thereby reducing false positives while maintaining detection capability.
2Productivity
If conventional serological tests are used, then the tests can screen for T. cruzi infection, but they exhibit variability in procedures and reagents between laboratories leading to inconclusive results
Solution Approach 1:
The patent standardizes the diagnostic approach by using a fixed array of discrete T. cruzi antigens with defined characteristics. This standardization of antigen presentation parameters across different laboratories eliminates procedural variability and ensures consistent, reproducible results while maintaining high screening throughput.
3Ease of operation
If a single antigen test is used, then the test is simple and rapid, but it cannot distinguish between different stages of infection or provide detailed diagnostic information
Solution Approach 1:
The patent creates a multi-functional diagnostic platform where a single array-based test can simultaneously detect multiple T. cruzi antigens. This enables the test to provide detailed information about infection stages, antigenic variants, and response patterns while maintaining operational simplicity. The same assay structure serves multiple diagnostic purposes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces false positives and enhances sensitivity, allowing for accurate detection of T. cruzi infections and monitoring of infection stages, vaccination status, and treatment efficacy, while also enabling screening of blood supplies for contamination.
Implementation Method 1
at least one antigenic T. cruzi polypeptide binds to an antibody present in the body fluid of the first mammal
Data Source
AI summary
A sensitive, multicomponent diagnostic test for infection with T. cruzi, the causative agent of Chagas disease, including methods of making and methods of use. Also provided is a method for screening T. cruzi polypeptides to identify antigenic polypeptides for inclusion as components of the diagnostic test, as well as compositions containing antigenic T. cruzi polypeptides.